Appointment of Director
HealthBeacon plc ("HealthBeacon" or "the Company"), a leader in devices and software to manage critical and chronic medications, is pleased to announcement the appointment of Mr Leo Toole as a Non-Executive Director of the Company [with immediate effect]. Upon appointment, Mr Toole will chair the Company's Audit and Risk Committee.
Mr Toole is currently Chief Financial Officer at Netherlands-based medical device company, ViCentra B.V. , and has extensive medical technology, pharmaceutical and capital markets experience as a senior finance leader. He has held senior finance roles with businesses including hVIVO plc (formerly Open Orphan plc), Sublimity Therapeutics Limited (formerly Sigmoid Pharma Limited), ResMed Inc and Procter and Gamble. He holds a Degree in Finance & Strategy from Trinity College Dublin and an MBA from INSEAD.
Robert Garber, Chairman of HealthBeacon plc, commented: "I am very pleased to welcome Leo to HealthBeacon's Board. Leo brings a wealth of financial experience across the healthcare and medical technology sectors, as well as public markets. His expertise will be invaluable as we continue to expand our client base, grow technology deployments, and deliver on the significant growth opportunity ahead."
-Ends-
| Enquiries: |
Investor.Relations@HealthBeacon.com |
| HealthBeacon: Jim Joyce Lar Malone
|
|
| Goodbody (Euronext Listing Sponsor and Broker): David Kearney |
+353 (1) 667 0420 |
| Stephen Kane |
|
|
Drury (Public Relations): |
|
| Cathal Barry |
+353 (0) 87 227 9281 |
| Paul Clifford |
+353 (0) 87 327 2161 |
About HealthBeacon
Headquartered in Dublin, HealthBeacon is an Irish digital therapeutics company that develops smart tools for managing medications for patients in the home. The HealthBeacon Injection Care Management System tracks adherence and persistence with medication schedules through the provision of medication management reminders, safe and sustainable sharps disposal devices, educational tools, and artificial intelligence (AI) driven data analytics. Peer reviewed evidence supports a 19% improvement in therapy persistence by patients and up to 26% improvement in adherence to therapy, which improves clinical outcomes and significantly improves efficiency in health systems. The Company has expanded its offering to growth management with the launch of its integrated Smart Scale and oral adherence with the launch of HB Wave which integrates with its existing technology. The Company operates across Europe, North America and the United Kingdom and employs more than 70 people and has obtained more than 30 design and utility patents. The Company's mission is to become the world's leading digital therapeutics platform for patients managing medications in the home.
Ends
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.